0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 82 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 6090514
Description Jump to:
Somatostatin analogs (SSAs) are synthetic peptides used to manage neuroendocrine tumors (NETs), acromegaly, and other hormonal disorders by inhibiting hormone secretion. The market is driven by rising NET diagnoses, with a global incidence of 6.98 per 100,000, and acromegaly’s prevalence of 60 per million. Long-acting formulations and oral SSAs like Mycapssa improve patient compliance, while increasing diagnosis rates and reimbursement policies boost adoption. SSAs are critical for 50% of NET patients and achieve 70% control in acromegaly. The aging population and advanced diagnostics further fuel demand. The global SSAs market is estimated at USD 3.0-6.0 billion in 2025, with a CAGR of 9%-14% through 2030.

Regional Market Trends

  • North America: The U.S. leads with advanced NET diagnostics, while Canada focuses on acromegaly management.
  • Europe: Germany, France, and the UK drive growth with strong reimbursement and oncology networks.
  • Asia Pacific: China and India see rising demand due to improved diagnostics, with Japan emphasizing long-acting SSAs.
  • Rest of the World: Brazil expands NET treatment access, while the Middle East invests in endocrinology care.

Application Analysis

  • Hospitals: Expected growth of 9.5%-14.5%, driven by NET and acromegaly treatment needs. Trends focus on infusion protocols.
  • Clinics: Projected growth of 9.2%-14.2%, linked to outpatient care. Advances emphasize patient compliance.
  • Others: Anticipated growth of 8.8%-13.8%, covering homecare settings. Trends highlight self-administration options.

Type Analysis

  • Octreotide: Expected growth of 9.3%-14.3%, valued for broad indications. Trends focus on oral formulations.
  • Lanreotide: Projected growth of 9.4%-14.4%, favored for NETs. Advances emphasize long-acting depot injections.
  • Pasireotide: Anticipated growth of 9.0%-14.0%, suited for resistant cases. Trends highlight combination therapies.
  • Others: Expected growth of 8.7%-13.7%, covering novel analogs. Developments prioritize bioavailability.

Key Market Players

  • Nordisk: Develops SSAs for hormonal disorders.
  • Ipsen: Offers long-acting lanreotide for NETs.
  • Pfizer: Provides octreotide formulations.
  • Sun Pharmaceutical: Focuses on affordable SSAs.
  • Camurus AB: Specializes in innovative delivery systems.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Low, due to high R&D costs and patent protections, though generics ease entry.
  • Threat of Substitutes: Moderate, with surgical options competing, but SSAs remain first-line for NETs.
  • Bargaining Power of Buyers: Moderate, as hospitals seek cost-effective options, but specialized indications limit choices.
  • Bargaining Power of Suppliers: Low, with multiple peptide manufacturers.
  • Competitive Rivalry: Moderate, with players competing on delivery and efficacy.

Market Opportunities and Challenges

Opportunities:

1. Addressing NETs, with rising incidence of 6.98 per 100,000.
2. Managing acromegaly, affecting 60 per million, with high control rates.
3. Leveraging long-acting and oral SSAs for better compliance.
4. Utilizing 65% SSA coverage in OECD countries.
5. Supporting advanced diagnostics for early NET detection.
6. Meeting demand from aging populations with hormonal disorders.

Challenges:

  • High costs of long-acting formulations.
  • Regulatory delays for novel analogs.
  • Limited access in low-income regions.
  • Competition from surgical and radiopharmaceutical treatments.
  • Side effects requiring patient monitoring.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Somatostatin Analogs Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Somatostatin Analogs Market in North America (2020-2030)
8.1 Somatostatin Analogs Market Size
8.2 Somatostatin Analogs Market by End Use
8.3 Competition by Players/Suppliers
8.4 Somatostatin Analogs Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Somatostatin Analogs Market in South America (2020-2030)
9.1 Somatostatin Analogs Market Size
9.2 Somatostatin Analogs Market by End Use
9.3 Competition by Players/Suppliers
9.4 Somatostatin Analogs Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Somatostatin Analogs Market in Asia & Pacific (2020-2030)
10.1 Somatostatin Analogs Market Size
10.2 Somatostatin Analogs Market by End Use
10.3 Competition by Players/Suppliers
10.4 Somatostatin Analogs Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Somatostatin Analogs Market in Europe (2020-2030)
11.1 Somatostatin Analogs Market Size
11.2 Somatostatin Analogs Market by End Use
11.3 Competition by Players/Suppliers
11.4 Somatostatin Analogs Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Somatostatin Analogs Market in MEA (2020-2030)
12.1 Somatostatin Analogs Market Size
12.2 Somatostatin Analogs Market by End Use
12.3 Competition by Players/Suppliers
12.4 Somatostatin Analogs Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Somatostatin Analogs Market (2020-2025)
13.1 Somatostatin Analogs Market Size
13.2 Somatostatin Analogs Market by End Use
13.3 Competition by Players/Suppliers
13.4 Somatostatin Analogs Market Size by Type
Chapter 14 Global Somatostatin Analogs Market Forecast (2025-2030)
14.1 Somatostatin Analogs Market Size Forecast
14.2 Somatostatin Analogs Application Forecast
14.3 Competition by Players/Suppliers
14.4 Somatostatin Analogs Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Nordisk
15.1.1 Company Profile
15.1.2 Main Business and Somatostatin Analogs Information
15.1.3 SWOT Analysis of Nordisk
15.1.4 Nordisk Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.2 Ipsen
15.2.1 Company Profile
15.2.2 Main Business and Somatostatin Analogs Information
15.2.3 SWOT Analysis of Ipsen
15.2.4 Ipsen Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.3 Pfizer
15.3.1 Company Profile
15.3.2 Main Business and Somatostatin Analogs Information
15.3.3 SWOT Analysis of Pfizer
15.3.4 Pfizer Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.4 Amryt Pharma
15.4.1 Company Profile
15.4.2 Main Business and Somatostatin Analogs Information
15.4.3 SWOT Analysis of Amryt Pharma
15.4.4 Amryt Pharma Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.5 Sun Pharmaceutical
15.5.1 Company Profile
15.5.2 Main Business and Somatostatin Analogs Information
15.5.3 SWOT Analysis of Sun Pharmaceutical
15.5.4 Sun Pharmaceutical Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.6 Peptron
15.6.1 Company Profile
15.6.2 Main Business and Somatostatin Analogs Information
15.6.3 SWOT Analysis of Peptron
15.6.4 Peptron Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.7 Fresenius Kabi
15.7.1 Company Profile
15.7.2 Main Business and Somatostatin Analogs Information
15.7.3 SWOT Analysis of Fresenius Kabi
15.7.4 Fresenius Kabi Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
15.8 Camurus AB
15.8.1 Company Profile
15.8.2 Main Business and Somatostatin Analogs Information
15.8.3 SWOT Analysis of Camurus AB
15.8.4 Camurus AB Somatostatin Analogs Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Somatostatin Analogs Report
Table Data Sources of Somatostatin Analogs Report
Table Major Assumptions of Somatostatin Analogs Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Somatostatin Analogs Picture
Table Somatostatin Analogs Classification
Table Somatostatin Analogs Applications
Table Drivers of Somatostatin Analogs Market
Table Restraints of Somatostatin Analogs Market
Table Opportunities of Somatostatin Analogs Market
Table Threats of Somatostatin Analogs Market
Table COVID-19 Impact For Somatostatin Analogs Market
Table Raw Materials Suppliers
Table Different Production Methods of Somatostatin Analogs
Table Cost Structure Analysis of Somatostatin Analogs
Table Key End Users
Table Latest News of Somatostatin Analogs Market
Table Merger and Acquisition
Table Planned/Future Project of Somatostatin Analogs Market
Table Policy of Somatostatin Analogs Market
Table 2020-2030 North America Somatostatin Analogs Market Size
Figure 2020-2030 North America Somatostatin Analogs Market Size and CAGR
Table 2020-2030 North America Somatostatin Analogs Market Size by Application
Table 2020-2025 North America Somatostatin Analogs Key Players Revenue
Table 2020-2025 North America Somatostatin Analogs Key Players Market Share
Table 2020-2030 North America Somatostatin Analogs Market Size by Type
Table 2020-2030 United States Somatostatin Analogs Market Size
Table 2020-2030 Canada Somatostatin Analogs Market Size
Table 2020-2030 Mexico Somatostatin Analogs Market Size
Table 2020-2030 South America Somatostatin Analogs Market Size
Figure 2020-2030 South America Somatostatin Analogs Market Size and CAGR
Table 2020-2030 South America Somatostatin Analogs Market Size by Application
Table 2020-2025 South America Somatostatin Analogs Key Players Revenue
Table 2020-2025 South America Somatostatin Analogs Key Players Market Share
Table 2020-2030 South America Somatostatin Analogs Market Size by Type
Table 2020-2030 Brazil Somatostatin Analogs Market Size
Table 2020-2030 Argentina Somatostatin Analogs Market Size
Table 2020-2030 Chile Somatostatin Analogs Market Size
Table 2020-2030 Peru Somatostatin Analogs Market Size
Table 2020-2030 Asia & Pacific Somatostatin Analogs Market Size
Figure 2020-2030 Asia & Pacific Somatostatin Analogs Market Size and CAGR
Table 2020-2030 Asia & Pacific Somatostatin Analogs Market Size by Application
Table 2020-2025 Asia & Pacific Somatostatin Analogs Key Players Revenue
Table 2020-2025 Asia & Pacific Somatostatin Analogs Key Players Market Share
Table 2020-2030 Asia & Pacific Somatostatin Analogs Market Size by Type
Table 2020-2030 China Somatostatin Analogs Market Size
Table 2020-2030 India Somatostatin Analogs Market Size
Table 2020-2030 Japan Somatostatin Analogs Market Size
Table 2020-2030 South Korea Somatostatin Analogs Market Size
Table 2020-2030 Southeast Asia Somatostatin Analogs Market Size
Table 2020-2030 Australia Somatostatin Analogs Market Size
Table 2020-2030 Europe Somatostatin Analogs Market Size
Figure 2020-2030 Europe Somatostatin Analogs Market Size and CAGR
Table 2020-2030 Europe Somatostatin Analogs Market Size by Application
Table 2020-2025 Europe Somatostatin Analogs Key Players Revenue
Table 2020-2025 Europe Somatostatin Analogs Key Players Market Share
Table 2020-2030 Europe Somatostatin Analogs Market Size by Type
Table 2020-2030 Germany Somatostatin Analogs Market Size
Table 2020-2030 France Somatostatin Analogs Market Size
Table 2020-2030 United Kingdom Somatostatin Analogs Market Size
Table 2020-2030 Italy Somatostatin Analogs Market Size
Table 2020-2030 Spain Somatostatin Analogs Market Size
Table 2020-2030 Belgium Somatostatin Analogs Market Size
Table 2020-2030 Netherlands Somatostatin Analogs Market Size
Table 2020-2030 Austria Somatostatin Analogs Market Size
Table 2020-2030 Poland Somatostatin Analogs Market Size
Table 2020-2030 Russia Somatostatin Analogs Market Size
Table 2020-2030 MEA Somatostatin Analogs Market Size
Figure 2020-2030 MEA Somatostatin Analogs Market Size and CAGR
Table 2020-2030 MEA Somatostatin Analogs Market Size by Application
Table 2020-2025 MEA Somatostatin Analogs Key Players Revenue
Table 2020-2025 MEA Somatostatin Analogs Key Players Market Share
Table 2020-2030 MEA Somatostatin Analogs Market Size by Type
Table 2020-2030 Egypt Somatostatin Analogs Market Size
Table 2020-2030 Israel Somatostatin Analogs Market Size
Table 2020-2030 South Africa Somatostatin Analogs Market Size
Table 2020-2030 Gulf Cooperation Council Countries Somatostatin Analogs Market Size
Table 2020-2030 Turkey Somatostatin Analogs Market Size
Table 2020-2025 Global Somatostatin Analogs Market Size by Region
Table 2020-2025 Global Somatostatin Analogs Market Size Share by Region
Table 2020-2025 Global Somatostatin Analogs Market Size by Application
Table 2020-2025 Global Somatostatin Analogs Market Share by Application
Table 2020-2025 Global Somatostatin Analogs Key Vendors Revenue
Figure 2020-2025 Global Somatostatin Analogs Market Size and Growth Rate
Table 2020-2025 Global Somatostatin Analogs Key Vendors Market Share
Table 2020-2025 Global Somatostatin Analogs Market Size by Type
Table 2020-2025 Global Somatostatin Analogs Market Share by Type
Table 2025-2030 Global Somatostatin Analogs Market Size by Region
Table 2025-2030 Global Somatostatin Analogs Market Size Share by Region
Table 2025-2030 Global Somatostatin Analogs Market Size by Application
Table 2025-2030 Global Somatostatin Analogs Market Share by Application
Table 2025-2030 Global Somatostatin Analogs Key Vendors Revenue
Figure 2025-2030 Global Somatostatin Analogs Market Size and Growth Rate
Table 2025-2030 Global Somatostatin Analogs Key Vendors Market Share
Table 2025-2030 Global Somatostatin Analogs Market Size by Type
Table 2025-2030 Somatostatin Analogs Global Market Share by Type

Companies Mentioned

  • Nordisk
  • Ipsen
  • Pfizer
  • Amryt Pharma
  • Sun Pharmaceutical
  • Peptron
  • Fresenius Kabi
  • Camurus AB

Related Topics

Related Reports

Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
EUR$5,850USDGBP
Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
EUR$3,250USDGBP
EUR$4,850USDGBP
Somatostatin Analogs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Somatostatin Analogs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
EUR$4,365USDGBP
EUR$4,850USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more